CIPO Refuses Regeneron’s Sarilumab Patent Application on Obviousness Grounds: Implications for Biopharma IP

Case Overview

The Parties

The Patent at Issue

This case involved Canadian Patent Application No. CA2851751A1, covering compositions comprising sarilumab — a fully human monoclonal antibody targeting the IL-6 receptor — in combination with methotrexate, a well-established disease-modifying antirheumatic drug (DMARD), and their use in treating rheumatoid arthritis. The 45 claims at issue encompassed composition claims and method-of-use claims related to this combination therapeutic approach.

• • Sarilumab compositions for RA — Fully human monoclonal antibody targeting IL-6 receptor.
• • Combination with methotrexate — Well-established DMARD for RA treatment.
• • Method-of-use claims — Therapeutic approach for rheumatoid arthritis.

The Verdict & Legal Analysis

Outcome

The Commissioner of Patents refused to grant patent CA2851751A1, affirming the Patent Appeal Board’s recommendation in its entirety. No damages are applicable in this administrative context. The refusal carries immediate commercial consequences: Regeneron cannot assert Canadian patent rights arising from this application against competitors, generics, or biosimilar manufacturers for the specific sarilumab-methotrexate combination compositions and methods described in the refused claims.

Verdict Cause Analysis: Obviousness Under Section 28.3

The central legal issue was obviousness, governed by section 28.3 of Canada’s Patent Act, which requires that claimed inventions not be obvious to a person skilled in the art as of the claim date, having regard to information disclosed publicly before that date.

The Patent Appeal Board concluded — and the Commissioner concurred — that all 45 claims lacked the requisite inventive step. While the specific prior art references are not enumerated in the available case record, the finding is analytically consistent with broader trends in pharmaceutical combination therapy prosecution: where both components of a combination are individually known, and where scientific rationale for combining them was well-established in the literature (in this instance, the clinical logic of pairing an IL-6 inhibitor with a conventional DMARD was extensively documented in RA treatment guidelines and clinical trial data predating the application), applicants face a steep burden to demonstrate unexpected results or synergistic efficacy that a skilled artisan would not have predicted.

The obviousness analysis under Canadian patent law follows a structured approach derived from *Apotex Inc. v. Sanofi-Synthelabo Canada Inc.*, [2008] 3 SCR 265, which established a four-part “obvious to try” test. Whether the Board applied an “obvious to try” framework or a straightforward “obvious” analysis is not specified in the available record, but either pathway leads to the same conclusion here given the prior art landscape for IL-6 receptor antagonism in RA combination therapy.

Legal Significance

This decision reinforces the high obviousness bar that combination therapy patent applications face at CIPO, particularly in therapeutic areas — such as rheumatoid arthritis — saturated with prior art. The refusal of a 45-claim application in its entirety signals that broad claim drafting strategies without strong evidence of unexpected advantages are unlikely to survive administrative review in Canada.

For pharmaceutical patent practitioners, this outcome highlights the importance of:

• Building a robust prosecution record that includes comparative efficacy data demonstrating non-obvious advantages of a combination over individual components or existing combinations.
• Proactive claim differentiation from known combination therapies at the drafting stage.
• Leveraging foreign prosecution outcomes — if corresponding U.S. or European applications have issued or survived obviousness challenges — as evidence of patentability in the Canadian record.

Strategic Takeaways

For Patent Holders & Prosecutors:
Combination therapy applications require more than compositional novelty. Prosecution strategy should front-load clinical or mechanistic evidence of unexpected synergy into the application as filed. Relying solely on the novelty of one component (e.g., a new biologic) within a known therapeutic framework is insufficient to establish inventive step under Canadian law.

For Accused Infringers & Generic/Biosimilar Manufacturers:
This refusal removes a potential IP barrier for Canadian manufacturers of sarilumab-methotrexate combination products, pending any Federal Court reversal. Biosimilar developers should monitor the appellate docket closely.

For R&D Teams:
Freedom-to-operate (FTO) analyses for RA combination therapies in Canada should account for this refusal. The unenforceability of CA2851751A1 may expand the commercial space for competing combination regimens.